Cediranib
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 12 to 35 hours |
Identifiers | |
| |
CAS Number | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.196.628 |
Chemical and physical data | |
Formula | C25H27FN4O3 |
Molar mass | 450.505 g/mol g·mol−1 |
3D model (JSmol) | |
| |
(verify) |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1][2][3]
It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader Avastin.
References
- ^ Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Goss G, Shepherd FA, Laurie S; et al. (2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45 (5): 782–8. doi:10.1016/j.ejca.2008.10.022. PMID 19091548.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Nikolinakos P, Heymach JV (2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296.
{{cite journal}}
: Unknown parameter|month=
ignored (help)
http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245
External links